Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts

Vor Biopharma Inc. (NYSE:VOR) has received an average rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have covered the stock in the last year is $11.36.

VOR has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Wedbush reiterated an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a report on Monday, December 9th. Robert W. Baird dropped their price target on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Rosalind Advisors Inc. bought a new stake in shares of Vor Biopharma in the 3rd quarter valued at about $54,000. Exchange Traded Concepts LLC boosted its holdings in Vor Biopharma by 40.8% in the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after acquiring an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma during the 2nd quarter valued at approximately $53,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Vor Biopharma during the 2nd quarter worth approximately $63,000. Finally, Hsbc Holdings PLC lifted its position in shares of Vor Biopharma by 177.0% in the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares during the period. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Stock Performance

Shares of VOR opened at $1.56 on Friday. Vor Biopharma has a 52-week low of $0.63 and a 52-week high of $3.14. The firm has a market cap of $106.79 million, a price-to-earnings ratio of -0.94 and a beta of -0.51. The business’s fifty day moving average is $0.99 and its 200-day moving average is $0.91.

Vor Biopharma (NYSE:VOR) last released its earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.40). As a group, research analysts forecast that Vor Biopharma will post -1.55 EPS for the current fiscal year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.